You are here: Industry Insights > Nektar

News List

Vaccibody, Nektar Announce First Patient Dosed in Study for Personalized Neoantigen Cancer Vaccine americanpharmaceuticalreview
August 17, 2020
Vaccibody AS and Nektar Therapeutics announced the first patient has been dosed in the combination therapy of the Phase 1/2a study ...
Faulty manufacturing trips up Nektar's Bristol-partnered cancer drug in crucial trial fiercepharma
August 13, 2019
Could a manufacturing mix-up be as detrimental as the fact that a drug simply doesn’t work? Nektar learned the answer the hard way with its Bristol-Myers Squibb-partnered experimental cancer therapy.
Nektar Therapeutics, BMS Receive Breakthrough Therapy Designation contractpharma
August 02, 2019
Bempegaldesleukin in combination with Bristol-Myers Squibb's Opdivo aims to treat patients with untreated advanced melanoma.
Trovagene Announces Collaboration with Nektar to Evaluate Onvansertib, ONZEALD™ americanpharmaceuticalreview
May 24, 2019
Trovagene and Nektar have entered into a research collaboration to explore the combination of Trovagene's PLK1 inhibitor, onvansertib, and Nektar's topoisomerase I inhibitor, ONZEALD ...
"Underwhelming" drug data devastates Nektar, shares fall by 42% pharmafile
June 07, 2018
Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with Bristol Myers-Squibb’s Opdivo at the American Society of Clinical Oncology (ASCO) annual event in Chicago.
Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors biospace
April 12, 2018
Nektar Therapeutics, Inc. today announced that it has initiated the administration of patients in 1/2 phase REVEAL clinical studies
Nektar Therapeutics appoints Mr. Jeff Ajer to its board of directors biospectrumasia
September 25, 2017
Mr. Ajer has more than 25 years of biotechnology industry experience within rare disease and specialty medicine.
Lilly and Nektar partner to develop new immunological therapy NKTR-358 pharmaceutical-technology
July 27, 2017
Eli Lilly and Company has entered a strategic collaboration to co-develop Nektar Therapeutics’ new immunological therapy NKTR-358.
Lilly, Nektar to co-develop new immunotherapy pharmatimes
July 26, 2017
Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million.
Nektar’s opioid analgesic meets endpoints in Phase 3 Study of chronic pain europeanpharmaceuticalreview
March 29, 2017
Nektar Therapeutics announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, an opioid analgesic.